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Abstract: Background: the safety and efficacy of cataract surgery in eyes with exudative neovascular
age-related macular degeneration (nAMD), receiving active treatment, remain unclear. We evaluated
the long-term outcomes and associated predictive factors of cataract surgery in eyes with exudative
nAMD. Methods: this retrospective cohort study included 65 eyes (61 patients) treated with anti-
vascular endothelial growth factor (VEGF) injections within six months preoperatively. Changes in
best-corrected visual acuity (BCVA) and anti-VEGF treatment patterns from before to up to four years
after surgery were assessed. Predictive factors were identified in association with one-year surgical
outcomes. Results: the BCVA improved at six months (p < 0.001) and was maintained for three
years postoperatively. The interval between anti-VEGF injections increased 3.4 times postoperatively
(p = 0.001). Risk factors for poor BCVA were low preoperative BCVA (p < 0.001) and prolonged nAMD
duration (p = 0.003). Prolonged nAMD duration and short exudation-free period were associated
with more frequent postoperative anti-VEGF treatments (p = 0.028 and p = 0.003, respectively). AMD
subtypes were not associated with both vision and injection pattern outcomes. Conclusions: patients
with cataracts receiving nAMD treatment can safely undergo surgery with favorable long-term visual
benefits. The preoperative BCVA, nAMD duration, and exudation-free period are potential predictors
of surgery outcomes.
Keywords: neovascular age-related macular degeneration; cataract surgery; anti-vascular endothelial
growth factor therapy; visual acuity; predictive factors
1. Introduction
Cataracts and age-related macular degeneration (AMD) are the leading causes of
vision impairment, especially in older patients [1,2]. The prevalence of these conditions
will increase proportionally in an aging global population. Advancements in cataract
surgery have facilitated the cost-effective and successful treatment of cataracts [3], and
the advent of anti-vascular endothelial growth factor (VEGF) agents has dramatically
improved the outcome of neovascular AMD (nAMD) treatment [4,5].
The effects of cataract surgery on non-exudative AMD have been investigated ex-
tensively in previous cross-sectional studies [6], randomized clinical studies [7–10], and
meta-analyses [11,12]. Most of these studies reported no significant association between
cataract surgery and the progression of non-exudative AMD. The safety and efficacy of
cataract surgery in patients with exudative nAMD have also been investigated, although in
a limited number of non-comparative [13–18] and comparative studies [19,20], conducted
in patients with nAMD who had and had not undergone cataract surgery. Most studies
have shown that cataract surgery is beneficial for vision improvement without exacerbating
the progression of AMD. However, some of these studies had notable limitations. Two
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non-comparative studies only included approximately 24–28% of the exudative status of
patients with AMD at the time of surgery [15,18]. In other studies, the participants were
not administered anti-VEGF (stable neovascular complex) agents in the six months prior to
surgery, or their preoperative exudation-free periods were not described in detail [13,15,17].
Moreover, the follow-up durations of these studies were limited to three months to one
year postoperatively [16,18,19].
A recent longitudinal study that analyzed data from a health insurance database
showed that cataract surgery is associated with an increased risk of nAMD [21]. The long-
term outcomes after cataract surgery, especially in the eyes of patients on active treatment
for nAMD, are still largely unknown.
The overall short-term safety of cataract surgery in patients with nAMD has been
confirmed; however, for patients receiving active treatment for nAMD, specific preoperative
factors that predict poor visual prognosis and recurring or worsened exudation remain
unclear. One study found that a short AMD duration and a long exudation-free period were
associated with reduced exudation after cataract surgery [17]. However, the predictors for
recently treated nAMD eyes are still unknown since this study only included exudation-free
eyes with nAMD.
The safety and efficacy of cataract surgery in eyes with nAMD receiving active treat-
ment remain unclear. Knowledge of the long-term outcomes and factors predicting them
would be of immense value for clinicians treating patients with visually significant cataracts
and exudative nAMD. Therefore, we conducted this study to determine the three-year out-
comes of cataract surgery and to identify the prognostic factors related to the progression
of exudative nAMD in eyes receiving active anti-VEGF therapy.
2. Materials and Methods
2.1. Study Design
This retrospective, observational cohort study used data extracted from the medical
records of the Severance Hospital of Yonsei University College of Medicine (a tertiary
referral center) at Sinchon and Gangnam, Seoul, Korea. Ethical approval was obtained
from the Institutional Review Board of Gangnam Severance Hospital (approval number,
3-2019-0378). The requirement for patient consent was waived because patient data were
anonymized. This study was conducted in adherence to the tenets of the Declaration
of Helsinki.
2.2. Study Population
Patients who underwent uneventful cataract surgery between 1 July 2006 and 31 Au-
gust 2019 while receiving anti-VEGF therapy for nAMD were considered for inclusion in
this study. The eyes of patients who were followed up for at least 12 months after cataract
surgery were included in the analysis. Only the eyes that received the last anti-VEGF
injection within six months before cataract surgery were selected.
We identified 277 eyes suitable for inclusion from 304 patients with AMD who un-
derwent cataract surgery; 82 eyes with no confirmed macular neovascularization before
surgery were excluded. Furthermore, 72 eyes were excluded due to other ophthalmic co-
morbidities (e.g., vitreous and submacular hemorrhage, retinal detachment, or retinoschisis)
or with a history of any intraocular surgery (e.g., anterior vitrectomy, pars plana vitrectomy,
or glaucoma surgery) that could affect vision. We also excluded 14 eyes that were followed
up for less than one year after surgery, while we had no limit for the preoperative follow-up
time. Moreover, we excluded 31 eyes that had received the last anti-VEGF injection more
than six months before surgery and 13 eyes that had received anti-VEGF injections within
an average interval of 6 months.
The primary outcome was analyzed in 65 eyes of 61 patients. Four patients had
bilateral AMD, and both eyes were included in the analyses. Among the included eyes,
43 had been followed up for at least one year pre- and postoperatively, as required for
comparing the frequency of anti-VEGF injections.
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2.3. Measurements and Outcomes
In addition to demographic data, we recorded the dates of nAMD diagnosis, cataract
surgery, and all anti-VEGF injections before and after surgery. We also investigated the
detailed history of anti-VEGF therapy (duration, type of drug used, injection regimen,
number of injections, and interval between injections) and cataract surgery (date, surgical
method, and combined procedures, such as anti-VEGF injection and anterior vitrectomy).
Injection regimens were divided into two: pro re nata (PRN) and treat-and-extend (TAE).
The baseline was defined as the time when the first anti-VEGF injection for nAMD treatment
was administered. The period before cataract surgery was referred to as “preoperative.” The
injections combined with cataract surgery were considered as “postoperative” treatment.
We evaluated the presence of exudation indicators (collection of fluid or hemorrhage
in the intraretinal or subretinal spaces) depending on the findings of optical computed
tomography (OCT). “Exudation-free” was defined as completely dry, with no exudation
indicators. The exudation-free period before cataract surgery was measured in days. All
eyes treated with the PRN regimen were included to evaluate the interval to the subsequent
recurrence; in the TAE regimen, we considered only those with exudation confirmed on
OCT at the first postoperative injection.
The primary outcome was the change in visual acuity (VA) at six months, one year,
and three years after cataract surgery. The secondary outcome was the identification
of postoperative factors that could predict the visual outcome. Variables considered in
the analyses of predictive factors included patient age, type of AMD lesion, the interval
between first and last intravitreal anti-VEGF injection and cataract surgery, preoperative
exudation-free period, and the presence of exudation during surgery.
2.4. Statistical Analysis
Descriptive data are presented as mean ± standard deviation (SD) or frequencies (with
percentages), as appropriate. A paired t-test was used to analyze differences before and
after cataract surgery. We used simple regression analysis with a linear mixed-effect model
to evaluate the relationship between each prognostic factor and the visual outcome and
frequency of anti-VEGF injections. Subsequently, we included the predictive prognostic
factors with the lowest p-values in a multiple regression model, created using a stepwise
backward selection procedure. All statistical analyses were conducted using SPSS software
version 21.0 (IBM, Armonk, NY, USA). A p-value < 0.05 was considered to indicate statistical
significance.
3. Results
3.1. Demographic and Clinical Characteristics
The patients’ demographic characteristics are summarized in Table 1. The initial
mean ± SD best-corrected visual acuity (BCVA) was 0.71 ± 0.45 logarithm of the minimum
angle of resolution (logMAR), and the mean BCVA before cataract surgery was 0.91 ± 0.45
logMAR. The average time between the diagnosis of nAMD and cataract surgery was
32.7 ± 32.9 months (range: 4–132). PRN injections were administered in 43 eyes (66.2%),
while 22 eyes (33.8%) were treated under the TAE regimen. Three cases treated with
the PRN regimen preoperatively switched to the TAE regimen after surgery, and no case
changed from TAE to PRN. The mean number of anti-VEGF injections administered during
the preoperative period was 14.2 ± 13.6.
Before cataract surgery, 20 eyes (30.8%) were treated with bevacizumab, 29 (44.6%)
with ranibizumab, and 16 (24.6%) with aflibercept. The average interval between the last
anti-VEGF injection and cataract surgery was 70.8 ± 55.8 days. The presence of exudative
fluid was confirmed using preoperative OCT examinations in 46 of 65 eyes (70.8%). A
total of 33 of 65 eyes (50.8%) received anti-VEGF injection combined with cataract surgery.
Among these eyes, 30 (90.9%) were originally scheduled for injection at approximately the
time of cataract surgery, and three (9.1%) received an additional injection to protect against
cataract surgery.
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Table 1. Characteristics of patients who underwent cataract surgery during active treatment
for nAMD.
Total p-Value
Basic characteristics (patients: n = 61)





Before cataract surgery (eyes: n = 65)
AMD duration, months 32.7 ± 32.9
AMD subtype, n (%)
MNV Type I 37 (57.0)
PCV 17 (26.2)
MNV Type II 8 (12.3)
MNV Type III 3 (4.6)
Regimen of anti-VEGF injections
Pro re nata 43 (66.2)
Treat-and-extend 22 (33.8)
Total number of anti-VEGF injections 14.2 ± 13.6
Interval from the last injection to surgery, days a 70.8 ± 55.8
Exudation-free period, days 23.0 ± 47.1
Anti-VEGF injection interval, days/injection b 66.5 ± 38.9
Cataract operation (eyes: n = 65)
Presence of exudation, n (%) 46 (70.8)
Phacoemulsification with IOL implantation, n (%) 32 (49.2)
Phacoemulsification with IOL implantation plus anti-VEGF, n (%) 33 (50.8)
After cataract surgery (eyes: n = 65)
Follow-up period, months 49.6 ± 37.8
Total number of anti-VEGF injection 12.4 ± 12.9
Interval to the subsequent injection, days a 88.1 ± 41.9 0.21
Anti-VEGF Injection interval, days/injection b 228.0 ± 39.2 0.001
Values are expressed as mean ± standard deviation (SD), or number of subjects and percentage, as appropriate.
a,b Used for paired t-test comparing intervals before and after surgery. nAMD: neovascular age-related macular
degeneration; VEGF: vascular endothelial growth factor; BCVA: best-corrected visual acuity; logMAR: logarithm
of the minimal angle of resolution; PCV: polypoidal choroidal vasculopathy; MNV: macular neovascularization;
IOL: intraocular lens.
3.2. Long-Term Changes in VA after Cataract Surgery
The change in BCVA after cataract surgery is shown in Figure 1. The BCVA signifi-
cantly improved six months (n = 65; 0.68 logMAR; p < 0.001) and one year (n = 65; 0.75
logMAR; p = 0.001) postoperatively compared to the preoperative BCVA (0.91 logMAR).
This improvement in vision was maintained for up to three years postoperatively (n = 51;
0.87 logMAR; p = 0.017).
The difference between the preoperative and postoperative BCVA was not significant
four years after cataract surgery (n = 39; 1.07 logMAR; p = 0.34). The postoperative BCVA
did not show any significant difference from the baseline BCVA at the time of nAMD
diagnosis up to three years after cataract surgery (p = 0.81 for six months, p = 0.94 for
one year, and p = 0.46 for three years postoperatively). However, the BCVA significantly
decreased four years postoperatively, compared to the baseline BCVA (p = 0.044).
3.3. Changes in Treatment Patterns after Cataract Surgery
The mean interval to the subsequent postoperative injection was 88.1 days, and there
was no significant difference when comparing the mean interval from the previous last
injection to the time of surgery (70.8 days, p = 0.21; Table 1). The average exudation-
free period increased significantly after surgery in the PRN regimen group (preoperative:
21.3 ± 10.4 days; postoperative: 112.9 ± 18.5; p = 0.004) and in the TAE regimen group
(preoperative: 26.3 ± 12.5 days; postoperative: 65.9 ± 16.4; p = 0.033). The average
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interval between injections increased significantly after surgery (preoperative: 66.5 days;
postoperative: 228.0 days; p = 0.001, Table 1). The average number of injections per
year decreased significantly from 5.2 before surgery to 1.6 after surgery (p = 0.001). The
mean injection interval significantly increased in the PRN regimen group (preoperative:
66.6 ± 34.3 days between injections; postoperative: 171.0 ± 15.7 days; p = 0.001), and
approached significance in the TAE regimen group, with approximately half of the subjects
(preoperative: 66.8 ± 44.7 days; postoperative: 234.3 ± 34.0 days; p = 0.064).




Figure 1. Changes in the mean best-corrected visual acuity from an average of 32.7 months before 
surgery (baseline), at the time of cataract surgery, and follow-ups. Number of patients at each time 
point: 65 (6M), 65 (1Y), 61 (2Y), 51 (3Y), and 39 (4Y). Values are expressed as mean ± standard devi-
ation (error bars). Statistical significance on a paired t-test (p < 0.05) when compared with the pre-
operative point is indicated by the asterisks (*) over the bars and when compared with baseline by 
the cross (†). M: months, Y: year(s), BCVA: best-corrected visual acuity, logMAR: logarithm of the 
minimum angle of resolution. 
The difference between the preoperative and postoperative BCVA was not signifi-
cant four years after cataract surgery (n = 39; 1.07 logMAR; p = 0.34). The postoperative 
BCVA did not show any significant difference from the baseline BCVA at the time of 
nAMD diagnosis up to three years after cataract surgery (p = 0.81 for six months, p = 0.94 
for one year, and p = 0.46 for three years postoperatively). However, the BCVA signifi-
cantly decreased four years postoperatively, compared to the baseline BCVA (p = 0.044). 
3.3. Changes in Treatment Patterns after Cataract Surgery 
The mean interval to the subsequent postoperative injection was 88.1 days, and there 
was no significant difference when comparing the mean interval from the previous last 
injection to the time of surgery (70.8 days, p = 0.21; Table 1). The average exudation-free 
period increased significantly after surgery in the PRN regimen group (preoperative: 21.3 
± 10.4 days; postoperative: 112.9 ± 18.5; p = 0.004) and in the TAE regimen group (preoper-
ative: 26.3 ± 12.5 days; postoperative: 65.9 ± 16.4; p = 0.033). The average interval between 
injections increased significantly after surgery (preoperative: 66.5 days; postoperative: 
228.0 days; p = 0.001, Table 1). The average number of injections per year decreased sig-
nificantly from 5.2 before surgery to 1.6 after surgery (p = 0.001). The mean injection inter-
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3.4. Predictive Factors for VA after Cataract Surgery 
The results of simple and multiple linear regression analyses of prognostic factors 
affecting BCVA one year after surgery are presented in Table 2. Higher preoperative 
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Figure 1. Changes in the mean best-corrected visual acuity from an average of 32.7 months before
surgery (baseline), at the time of cataract surgery, and follow-ups. Number of patients at each time
point: 65 (6M), 65 (1Y), 61 (2Y), 51 (3Y), and 39 (4Y). Values are expressed as mean ± standard
deviati n (error bars). Statisti l sig ificance on a paired t-test (p < 0.05) when com ared with the
reop rative point is indicat d by the asterisks (*) over the bars and when compared with baseline
by the cross (†). M: months, Y: year(s), BCVA: best-corrected visual acuity, logMAR: logarithm of the
minimum angle of resolution.
3.4. Predictive Factors for VA after Cataract Surgery
The results of simple and multiple linear regression analyses of prognostic factors
affecting BCVA one year after surgery are presented in Table 2. Higher preoperative BCVAs
were significantly associated with favorable VA outcomes (coefficient [CE]: 0.50; p < 0.001).
A shorter AMD duration was also associated with a more favorable postoperative VA (CE:
0.004; p = 0.003).
Table 2. Analysis of prognostic factors associated with postoperative BCVA (logMAR) at one year.
Factors
Simple Multiple
Coefficient (SE) p-Value Coefficient (SE) p-Value
Age 0.001 (0.004) 0.76
Preoperative BCVA a 0.68 (0.093) <0.001 0.50 (0.10) <0.001
AMD duration a 0.006 (0.002) 0.001 0.004 (0.001) 0.003
AMD subtype 0.07 (0.098) 0.48
Exudation-free period −0.003 (0.001) 0.61
Presence of exudation at surgery 0.15 (0.12) 0.22
Injection interval, preoperative 0.001 (0.001) 0.39
Combined anti-VEGF during cataract surgery −0.08 (0.048) 0.11
Interval to subsequent recurrence 0.001 (0.001) 0.22
a Factors with the lowest p-values in a simple linear regression analysis (i.e., p < 0.10) were included in a multiple regression analysis. SE:
standard error; BCVA: best-corrected visual acuity; logMAR: logarithm of the minimal angle of resolution; AMD: age-related macular
degeneration; VEGF: vascular endot elial growth factor.
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Other factors had no significant predictive effects, including age (p = 0.76), AMD
lesion subtype (p = 0.48), preoperative exudation-free period (p = 0.61), presence of exuda-
tion at surgery (p = 0.22), injection interval before surgery (p = 0.39), combined injection
during cataract surgery (p = 0.11), and subsequent recurrence of exudation postoperatively
(p = 0.22).
3.5. Predictive Factors for Anti-VEGF Injection Frequency after Cataract Surgery
Table 3 summarizes the results of simple and multiple linear regression analyses
of prognostic factors affecting the interval between anti-VEGF treatments after cataract
surgery. A longer AMD duration before cataract surgery was associated with an increased
frequency of injections afterward (CE: −3.38; p = 0.028). A prolonged exudation-free period
was associated with less frequent injections postoperatively (CE: 2.77; p = 0.003).
Other factors had no discernible predictive effects, including age (p = 0.49), AMD
lesion subtype (p = 0.14), the presence of exudation at surgery (p = 0.18), frequency of
injections before surgery (p = 0.17), combined injection during cataract surgery (p = 0.67),
and subsequent recurrence of exudation after surgery (p = 0.71).
Table 3. Analysis of prognostic factors associated with the interval of postoperative anti-VEGF injections.
Factors
Simple Multiple
Coefficient (SE) p-Value Coefficient (SE) p-Value
Age −1.51 (6.25) 0.49
Diabetes −14.5 (94.7) 0.74
AMD duration a −3.50 (1.60) 0.034 −3.38 (1.50) 0.028
AMD subtype 0.20 (1.50) 0.14
Exudation-free period a 1.91 (1.02) 0.010 2.77 (0.88) 0.003
Presence of exudation at surgery −118.7 (88.3) 0.18
Injection frequency, preoperative 1.68 (1.20) 0.17
Combined anti-VEGF during cataract surgery 27.1 (90.3) 0.67
Interval to subsequent recurrence 0.05 (0.8) 0.71
a Factors with the lowest p-values in a simple linear regression analysis (i.e., p < 0.10) were included in a multiple regression analysis. SE:
standard error; AMD: age-related macular degeneration; VEGF: vascular endothelial growth factor.
4. Discussion
We analyzed the outcomes of cataract surgery in eyes receiving active anti-VEGF
treatment for exudative nAMD. The postoperative VA recorded six months after cataract
surgery improved by 0.23 logMAR (0.12 Snellen equivalent) compared to the preoperative
VA; this improvement was maintained until the three-year follow-up. The mean interval
between anti-VEGF injections increased approximately 3.4 times postoperatively, and the
mean exudation-free period almost quadrupled. These postoperative changes were more
pronounced in the PRN regimen group compared to the TAE regimen group. The change
in injection frequency may coincide with the long-term natural course of nAMD after
treatment [22]. A low preoperative VA and long AMD duration were significant risk factors
for a poor visual outcome. The preoperative AMD duration and the exudation-free period
showed a significant association with the increased frequency of postoperative anti-VEGF
injections.
The eyes included in this study were being actively treated with anti-VEGF injections
at an interval of approximately two months before cataract surgery; this interval is rel-
atively shorter than that reported by previous studies [13,15–17,19,20]. The presence of
exudation was confirmed with OCT in 46 (70.8%) eyes included in this study, representing
a higher proportion of the total sample than previously reported [15,18]. In these cases,
the exudation-free period was considered zero, and the average exudation-free period
(21.3 days) was much shorter than the average interval between injections (66.5 days).
This difference appears because about half of the subjects (45.9%) have an average inter-
val between injections of longer than two months due to stable, non-progressive disease,
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even with minimal exudation. Despite the presence of active choroidal neovasculariza-
tion lesions, VA showed significant improvement for up to three years postoperatively.
Moreover, the postoperative recurrence rate of exudation decreased. Previous studies
have either reported no change [13,19] or marginal reduction [15] in the number of injec-
tions administered before and after surgery, with follow-up periods of several months to
one year.
We have complemented some previously reported predictive factors of visual out-
comes [17,18] by following up eyes under active anti-VEGF treatment for nAMD for over
three years. It may be difficult to obtain sufficient visual outcomes after cataract surgery if
the duration of AMD spans several years, with extremely poor preoperative vision. The
exudation-free period and postoperative presence of exudation had no discernible effects
on the visual outcome. More frequent postoperative visits are recommended to evaluate
exudation recurrence in patients with prolonged AMD and a short exudation-free period.
Unexpectedly, the frequency of preoperative injections and the combination of injections
with cataract surgery did not affect AMD progression postoperatively.
This study had some limitations. First, the study design was retrospective. Second,
we included eyes with heterogenous AMD subtypes, treated with a variety of anti-VEGF
agents and treatment regimens. However, this diversity could also be viewed as a strength
of the generalizability of our results. The absence of a matched control group that received
anti-VEGF therapy and no cataract surgery is also a limitation.
The present study also has several strengths. First, a detailed analysis of pertinent
data was performed, including VA and OCT results, before (32.7 months) and after cataract
surgery (up to 49.6 months). Second, we identified the long-term conditions of nAMD
and visual improvements after cataract surgery in eyes with exudative nAMD undergoing
active treatment. Third, the preoperative VA, nAMD duration, and exudation-free period
were identified as predictive factors under these clinical conditions.
5. Conclusions
In conclusion, we suggest that cataract surgery could be performed safely in eyes
with exudative nAMD receiving active anti-VEGF treatment. The different exudation-
free periods and nAMD durations may provide clinicians with useful information for
determining the optimal timing of cataract surgery. Preoperative VA is the most effective
predictive factor for determining the long-term postoperative visual outcome after cataract
surgery. Long-term clinical trials conducted under controlled conditions are needed to
validate the conclusions of this study.
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